Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course

Journal of Virology

Volumn 75, Issue 5, 2001, Pages 2246-2252

  Beaumont, T ^a   Van Nuenen, A ^a   Broersen, S ^a   Blattner, W A ^a   Lukashov, V V ^a   Schuitemaker, H ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; NEUTRALIZING ANTIBODY;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LABORATORY PERSONNEL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; CELL LINE; DISEASE PROGRESSION; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LABORATORY PERSONNEL; MACROPHAGES; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; OCCUPATIONAL EXPOSURE; PHENOTYPE; PHYLOGENY; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE ANALYSIS, DNA;

EID: 0035128422     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.5.2246-2252.2001     Document Type: Article

References (66)

1. Autologous HIV-1 neutralizing antibodies: Emergence of neutralization resistant escape virus and subsequent development of escape virus neutralizing antibodies
2. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
3. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies
4. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system
5. Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees
6. A rapid and simple method for purification of nucleic acids
7. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors
8. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
9. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
10. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
11. Neutralizing antibodies are positively associated with CD4T-cell counts and T-cell function in long term AIDS-free infection
12. Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals
13. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)
14. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
15. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects
16. Core structure of gp41 from the HIV envelope glycoprotein
17. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
18. Viral persistence in vivo through selection of neutralizing antibody-escape variants
19. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein
20. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker
21. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies
22. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule
23. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression
24. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells
25. MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers
26. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
27. Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants
28. Increasing genotype and phenotypic selection from the original genomic RNA populations of HIV-1 strains LAI and MN (NM) by peripheral blood mononuclear cell culture, B-cell-line propagation and T-cell-line adaptation
29. Intrahost human immunodeficiency virus type 1 evolution is related to the length of the immunocompetent period
30. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
31. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
32. Human immunodeficiency virus type I mutants that escape neutralization by human monoclonal antibody IgG1b12
33. Evidence that antibodymediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
34. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus
35. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
36. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1
37. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
38. Quantitation of HIV-1specific cytotoxic T lymphocytes and plasma load of viral RNA
39. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific T lymphocytes: Correlation with disease progression
40. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
41. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
42. Role of glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein
43. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
44. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers
45. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccines
46. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
47. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with non-progressive infection
48. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection
49. Viral variability and serum antibody response in a laboratory worker infected with the HIV type 1 (HTLV type IIIB)
50. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
51. Macrophage-tropic HIV-1 variants: Initiators of infection and AIDS pathogenesis?
52. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations
53. Monocytotropic human immunodeficiency virus 1 (HIV-1) variants detectable in all stages of HIV infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture
54. Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies
55. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV1/SIV chimeric virus infection of macaque monkeys
56. CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages
57. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag
58. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
59. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion
60. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission
61. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers
62. Atomic structure of the ectodomain from HIV-1 gp41
63. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
64. The antigenic structure of the HIV gp120 envelope protein
65. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1?